Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Ingle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityResidency, Internal Medicine, 1975 - 1976
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1973 - 1975- Johns Hopkins UniversityResidency, Internal Medicine, 1971 - 1973
- Johns Hopkins University School of MedicineClass of 1971
Certifications & Licensure
MN State Medical License 1976 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Centricity Enterprise, GE Healthcare, 2014
- CMS Meaningful Use Stage 1 Certification Centricity Patient Online, GE Healthcare, 2014
- CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014
Clinical Trials
- Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer Start of enrollment: 1995 Oct 01
- Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy Start of enrollment: 1997 Dec 02
- Combination Chemotherapy in Treating Patients With Breast Cancer Start of enrollment: 1997 Sep 01
Publications & Presentations
PubMed
- CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.Andrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, Annapoorna Venkatachalam, Annabella R Strathman
NPJ Breast Cancer. 2025-10-24 - 1 citationsReply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer".Matthew P Goetz, Grace M Choong, Tanya L Hoskin, Judy C Boughey, Sameera R Wijayawardana
Journal of Clinical Oncology. 2025-10-20 - Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.Judith-Anne W Chapman, Jane Bayani, Sandip SenGupta, John M S Bartlett, Tammy Piper
Breast Cancer Research and Treatment. 2025-08-01
Journal Articles
- ERβ-Mediated Induction of Cystatins Results in Suppression of TGFβ Signaling and Inhibition of Triple-Negative Breast Cancer MetastasisMatthew P Goetz, James N Ingle, Proceedings of the National Academy of Sciences
Press Mentions
Stress Reduction for Cancer Patients – Blowing BubblesOctober 7th, 2018- Transdermal Breast Cancer TreatmentsSeptember 28th, 2018
Genotyping Errors Plague CYP2D6 Testing for Tamoxifen TherapyDecember 10th, 2014
Grant Support
- Mayo Clinic Breast Cancer SporeNational Cancer Institute2005–2011
- Developmental Research ProgramNational Cancer Institute2008–2009
- Administrative CoreNational Cancer Institute2008–2009
- Career Development ProgramNational Cancer Institute2005–2009
- C1- Administrative CoreNational Cancer Institute2005
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
